| Zhou, Jian |
NCT05063071: Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant |
|
|
| Active, not recruiting | 4 | 150 | RoW | Tenofovir Alafenamide 25 MG | Fudan University | HBV, POST LIVER TRANSPLANT | 07/22 | 12/22 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC |
|
|
| Completed | 2 | 30 | RoW | Donafenib, PD-1, TACE | Shanghai Zhongshan Hospital | Donafenib | 04/24 | 05/24 | | |
NCT06530784: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | Cryoablation, PD-1 antibody and bevacizumab | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 12/25 | 05/26 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Zhongshan Hospital | Donafenib, Hepatocellular Carcinoma | 01/24 | 03/24 | | |
NCT05941286: Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital |
|
|
| Recruiting | N/A | 527 | RoW | CGM system with both glucose predictive alerts and threshold alerts on, CGM system with only glucose threshold alerts on, CGM system with glucose alerts off | Shanghai 6th People's Hospital | Diabetes Mellitus | 08/25 | 09/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT06591286: Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control |
|
|
| Recruiting | N/A | 150 | RoW | RT-CGM, SMBG | Shanghai 6th People's Hospital | Diabetes Mellitus, Type 2 | 03/26 | 09/27 | | |
NCT06662630: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients |
|
|
| Recruiting | N/A | 30 | RoW | High-Frequency Oscillatory Ventilation | Shanghai Zhongshan Hospital | Atelectasis, Acute Respiratory Distress Syndrome, VAP - Ventilator Associated Pneumonia | 10/25 | 10/26 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
NCT05707585: Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage |
|
|
| Recruiting | N/A | 2064 | RoW | Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH) | The Second Affiliated Hospital of Dalian Medical University, Fudan University, Zongda Hospital affiliated to Southeast University, West China Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shengjing Hospital, The First Affiliated Hospital of Guangzhou Medical University, Lisen Imprinting Diagnostics, Inc. | Lung Cancer | 01/24 | 07/24 | | |
